Hsiang-Lin Chan1,2, Wei-Che Chiu3,4, Vincent Chin-Hung Chen1,5, Kuo-You Huang6, Tsu-Nai Wang7, Yena Lee8, Roger S McIntyre8,9, Tsai-Ching Hsu10,11,12, Charles Tzu-Chi Lee13, Bor-Show Tzang10,11,12,14. 1. Department of Psychiatry, Chang Gung University, Taoyuan, Taiwan. 2. Department of Child Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. 3. Department of Psychiatry, Cathay General Hospital, Taipei, Taiwan. 4. School of Medicine, Fu Jen Catholic University, Taipei, Taiwan. 5. Department of Psychiatry, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan. 6. Department of Speech, Language Pathology and Audiology, Chung Shan Medical University, Taichung, Taiwan. 7. Department of Public Health, College of Health Science, Kaohsiung Medical University, Kaohsiung, Taiwan. 8. Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Canada. 9. Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada. 10. Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan. 11. Immunology Research Center, Chung Shan Medical University, Taichung, Taiwan, ROC. 12. Clinical Laboratory, Chung Shan Medical University Hospital, Taichung, Taiwan. 13. Department of Health Promotion and Health Education, National Taiwan Normal University, Taipei, Taiwan. 14. Department of Biochemistry, School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. OBJECTIVE: The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. METHODS: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables. RESULTS: All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend < .001). CONCLUSIONS: All kinds of SSRIs were associated with decreased risk of HCC.
BACKGROUND:Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. OBJECTIVE: The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. METHODS: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables. RESULTS: All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend < .001). CONCLUSIONS: All kinds of SSRIs were associated with decreased risk of HCC.
Authors: Quirino Lai; Alessandro Vitale; Tommaso M Manzia; Francesco G Foschi; Giovanni B Levi Sandri; Martina Gambato; Fabio Melandro; Francesco P Russo; Luca Miele; Luca Viganò; Patrizia Burra; Edoardo G Giannini Journal: Cancers (Basel) Date: 2019-10-15 Impact factor: 6.639